|

A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients

RECRUITINGSponsored by Novartis Pharmaceuticals
Actively Recruiting
SponsorNovartis Pharmaceuticals
Started2026-03-15
Est. completion2027-03-03
Eligibility
Age1 Year+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07517250

Summary

This study aims to assess and characterize the treatment patterns, and long-term clinical outcomes and demographic characteristics of patients diagnosed with Familial Mediterranean fever (FMF) and Still's disease (including systemic juvenile idiopathic arthritis \[SJIA\] and adult-onset Still's disease \[AOSD\]) that received canakinumab for at least 6 months.

Eligibility

Age: 1 Year+Healthy volunteers accepted
Inclusion criteria:

* Pediatric or adult patients who were prescribed canakinumab before October 2021 and received canakinumab for at least 6 months for the treatment of FMF or Still's disease (including SJIA or AOSD).
* Have data on clinical characteristics and treatments available for at least 3 years following the initiation of canakinumab treatment.

Exclusion criteria:

• Patients Aged \<2 Years (24 Months) at Index Date.

Conditions5

Adult Onset Still DiseaseArthritisFamilial Mediterranean FeverStill DiseaseSystemic Juvenile Idiopathic Arthritis

Browse More Trials

Arthritis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.